Digests

Decision Information

Decision Content

Apotex Inc. v. Wellcome Foundation Ltd.

T-3197-90 / T-2983-93 / T-2624-91

Tremblay-Lamer J.

13/5/96

26 pp.

Motion to strike from pleadings names of two scientists listed as inventors on basis of: (1) R. 419; and (2) issue estoppel-Pleadings submitted by Apotex and Novopharm alleging Wellcome Inc. scientists not making invention; however, subsequent admissions by Apotex and Novopharm recognizing two Wellcome scientists also inventors-Positive finding of admission-Appropriate naming of inventors constituting material allegation capable of rendering patent invalid and must be determined at trial-Possibility of wilful or misleading misnaming of inventor relevant issues not to be decided during pre-trial motion-Pleadings not clearly meeting R. 419 criteria; motion to strike based on R. 419 denied-Wellcome also submitting allegation of inventorship to be estopped on basis issue clearly decided in U.S.A.-Inventorship issue not to be estopped as American courts not hearing evidence from scientists-at-issue named by Apotex and Novopharm facing strong case of solicitor- client cost if, as in U.S.A., Court finding no legally sufficient evidentiary basis of any inventive contribution from Apotex and Novopharm scientists-Wording of American claims and Canadian claim different-Issues under American patent law and Canadian patent law different: reasonable basis for sound prediction not legally relevant in U.S.A. but relevant in Canada (Monsanto Company v. Commissioner of Patents, [1979] 2 S.C.R. 1108)-Motion to strike on basis of issue estoppel denied-Wellcome also submitting new use for purposes of medical treatment of known substance cannot be claimed as invention (Tennessee Eastman v. Commission of Patents, [1974] S.C.R. 111)-Whether patent "invention" important element of attack to validity of patent to be decided at trial; whether patent method of treatment claim factual question to be decided at trial-Case at bar distinguished from Merck & Co. v. Apotex Inc. (1994), 59 C.P.R. (3d) 133 (F.C.T.D.), holding fact ingredients of formulation of patent well-known having no bearing on validity of invention, on grounds compound claims not embodied in same patent; thus issue whether formulation can be claimed in absence of corresponding compound claim remaining open for trial judge-Lone fact scientists collecting experimental data insufficient to suggest inventorship-Twofold test applied with regards to allowing pleadings: (1) should assist in determination of real questions in controversy; and (2) will create no prejudice to opposing party with respect to discovery or amendment of preparation for trial-Amendments allowed in part-Federal Court Rules, C.R.C., c. 663, R. 419.

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.